Veeva Systems Inc. (VEEV) Stock Analysis 2026

HealthcareLife Sciences Cloud Software
$260.21
as of 2026-09-18
-5.0% (52-week)50D MA $212.78  |  200D MA $198.73

BriMind AI Score

Proprietary
59
Moderate
Price CAGR
20.6%
1Y Return
-5.1%
Analyst Upside
+12.1%
Rev Growth
17.6%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

About Veeva Systems Inc.

Veeva Systems is the dominant cloud software provider for the life sciences industry, building software specifically for pharmaceutical, biotech, and medical device companies. Its products cover commercial operations (CRM for pharma sales reps), regulatory affairs (vault for managing drug approval submissions), clinical data management, quality management, and safety reporting. Veeva's industry-specific focus creates deep product-market fit that horizontal software vendors like Salesforce cannot replicate.

How Veeva Systems Makes Money

Veeva earns primarily through multi-year subscription licenses for Vault (its content and data management platform) and Veeva CRM (commercial CRM for life sciences). The company has a land-and-expand model — customers start with one product and add others as Veeva expands its product suite. Enterprise contracts are typically 3-5 years, providing high revenue visibility. Veeva has transitioned from Salesforce platform dependency to its own Vault platform.

Veeva Systems Revenue & Profitability Breakdown

This chart shows how Veeva Systems's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$3.46B
Cost of Revenue
-$865.9M
Gross Profit
$2.59B75.0% margin
Operating Expenses
-$1.57B
Operating Income
$1.02B29.6% margin
Tax & Other
-$10.1M
Net Income
$1.01B29.3% margin
Gross Margin
75.0%
Operating Margin
29.6%
Net Margin
29.3%

Key Financial Metrics

Veeva Systems Inc. trades at a trailing P/E of 46.10x, generates $1.26B in free cash flow, runs a debt/equity ratio of 2.04, and converts shareholder equity into profit at a 14.4% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$45.45B
P/E (Trailing)
46.10
P/E (Forward)
27.41
PEG Ratio
1.24
Price / Book
6.26
Revenue
$3.46B
Revenue Growth
17.6%
Earnings Growth
39.5%
EPS (Trailing)
$6.09
EPS (Forward)
$10.24
Gross Margin
75.0%
Operating Margin
29.6%
Net Margin
29.3%
Return on Equity
14.4%
Return on Assets
7.6%
Free Cash Flow
$1.26B
Debt / Equity
2.04
Current Ratio
5.46
Quick Ratio
5.36
Beta
0.92
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
8.6%
Inst. Ownership
93.7%
Short % Float
3.9%
Book Value / Share
$44.83

Wall Street Analyst Consensus

Wall Street analysts covering Veeva Systems Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $294.07 (+13.0% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$294.07+13.0% upside

Intrinsic Value Estimates for VEEV

We use 3 valuation models to estimate VEEV's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

VEEV is currently in a golden cross pattern, trading above its 50-day average of $212.78 and above its 200-day average of $198.73. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$260.21
50-Day MA
$212.78
▲ Price above
200-Day MA
$198.73
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

VEEV Investment Case: Bull vs Bear

VEEV's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Bull Case (Reasons to Buy)

  • Life sciences software is a specialist market — generic horizontal SaaS cannot replicate the regulatory knowledge, industry workflows, and compliance requirements baked into Veeva's products.
  • Every major pharma and biotech company globally relies on Veeva products, creating a near-captive customer base with extremely high switching costs and renewal rates.
  • Veeva is expanding into clinical and safety applications, data cloud (commercial data as a service), and development cloud — each representing significant incremental TAM from existing customers.
  • Pharma R&D spending is growing as GLP-1 drugs, cell & gene therapy, and AI drug discovery fund new clinical trials — all requiring Veeva's Vault Clinical and regulatory products.

Bear Case (Key Risks)

  • Veeva's transition away from Salesforce's platform (building its own CRM on Vault) risks alienating customers who rely on Salesforce integration.
  • Life sciences industry consolidation through M&A can temporarily reduce customer count as merged pharma companies standardize on fewer tools.
  • Veeva's growth rate has moderated from hypergrowth as the business scales — sustaining 15-20% growth on a large revenue base requires successfully monetizing new product areas.
  • Regulatory changes in pharmaceutical approval processes could require significant Veeva product updates that increase R&D costs.

What to Watch: VEEV Key Metrics

Subscription revenue growth
Net revenue retention rate
Vault product adoption breadth
R&D pipeline customer expansion
Operating margin

VEEV Stock — Frequently Asked Questions

Read the full VEEV in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for Veeva Systems Inc..

Compare VEEV with Peers

VEEV vs CRMVeeva Systems vs Salesforce — Life Sciences CRM vs Gene
VEEV vs IQVVeeva Systems vs IQVIA — Life Sciences Tech vs Data Ana
VEEV vs HUBSVeeva Systems vs HubSpot — Life Sciences CRM vs SMB Mar
VEEV vs SNOWVeeva Systems vs Snowflake — Life Science Vertical SaaS
TEM vs VEEVTempus AI vs Veeva Systems — Precision Medicine Data Pl
DOCS vs VEEVDoximity vs Veeva Systems — Physician Network vs Life S
VEEV vs MDRXVeeva Systems vs Veradigm — Which Healthcare Software S

Unlock the Full VEEV Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis